Literature DB >> 18691502

Protein S is a cofactor for tissue factor pathway inhibitor.

J Rosing1, L F A Maurissen, S N Tchaikovski, G Tans, T M Hackeng.   

Abstract

Protein S is a vitamin K-dependent protein that acts as a cofactor of the anticoagulant protein APC. However, protein S also exhibits anticoagulant activity in the absence of APC. Thrombin generation experiments in normal plasma and in plasma deficient in tissue factor pathway inhibitor (TFPI) and/or protein S demonstrated that protein S stimulates the inhibition of TF by TFPI. Kinetic analysis in model systems containing purified proteins showed that protein S enhances the formation of the binary FXa:TFPI complex by reducing the Ki of TFPI from approximately 4 nM to approximately 0.5 nM. Enhancement of inhibitory activity of TFPI by protein S is only observed with full-length TFPI and in the presence of a negatively charged phospholipid surface. The Ki decrease brings the TFPI concentration necessary for FXa:TFPI complex formation within range of the plasma TFPI concentration which increases FXa:TFPI complex formation and accelerates feedback inhibition of the TF pathway by enhancing the formation of the quaternary TFPI:FXa:TF:FVIIa complex. Thus, protein S is not only a cofactor of APC, but also of TFPI. A reduced TFPI cofactor activity may contribute to the increased risk of venous thrombosis in protein-S deficient individuals. Using calibrated automated thrombography we have developed two assays that enable quantification of the functional activity of the TFPI/protein S system in plasma. These assays show that the activity of the TFPI/protein S system is greatly impaired in oral contraceptive users.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18691502     DOI: 10.1016/S0049-3848(08)70021-5

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

1.  Generation and phenotypic analysis of protein S-deficient mice.

Authors:  François Saller; Anne C Brisset; Svetlana N Tchaikovski; Monica Azevedo; Roman Chrast; José A Fernández; Marc Schapira; Tilman M Hackeng; John H Griffin; Anne Angelillo-Scherrer
Journal:  Blood       Date:  2009-06-30       Impact factor: 22.113

2.  Anticoagulant Protein S Targets the Factor IXa Heparin-Binding Exosite to Prevent Thrombosis.

Authors:  William E Plautz; Vijaya Satish Sekhar Pilli; Brian C Cooley; Rima Chattopadhyay; Pamela R Westmark; Todd Getz; David Paul; Wolfgang Bergmeier; John P Sheehan; Rinku Majumder
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-02-01       Impact factor: 8.311

Review 3.  Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants.

Authors:  Megan O Nakashima; Heesun J Rogers
Journal:  Blood Res       Date:  2014-06-25

4.  Quantitative Systems Pharmacology Model to Predict the Effects of Commonly Used Anticoagulants on the Human Coagulation Network.

Authors:  S Hartmann; K Biliouris; L J Lesko; U Nowak-Göttl; M N Trame
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-09-20

5.  Modulation of protein S and growth arrest specific 6 protein signaling inhibits pancreatic cancer cell survival and proliferation.

Authors:  Vijaya S Pilli; Arani Datta; Adrianne Dorsey; Bo Liu; Rinku Majumder
Journal:  Oncol Rep       Date:  2020-07-15       Impact factor: 3.906

6.  Pathophysiology of Antiphospholipid Syndrome.

Authors:  David Green
Journal:  Thromb Haemost       Date:  2021-11-18       Impact factor: 6.681

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.